ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

Polymorphs and hydrates of Etoricoxib, a selective COX-2 inhibitor

Grobelny, Pawel and Mukherjee, Arijit and Desiraju, Gautam R (2012) Polymorphs and hydrates of Etoricoxib, a selective COX-2 inhibitor. In: CRYSTENGCOMM, 14 (18). pp. 5785-5794.

[img] PDF
CRY_14-18_5787_2012.pdf - Published Version
Restricted to Registered users only

Download (1MB) | Request a copy
[img] PDF
c2ce06604a.pdf - Published Supplemental Material
Restricted to Registered users only

Download (600kB) | Request a copy
[img] Plain Text
c2ce06604a.txt - Published Supplemental Material
Restricted to Registered users only

Download (68kB) | Request a copy
Official URL: http://dx.doi.org/10.1039/c2ce06604a

Abstract

The crystal structures of two polymorphs and two polymorphic hemihydrates of Etoricoxib are reported. Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that is a selective inhibitor of COX-2. It is used in the treatment of various types of inflammation, pain and fever. Clas et al. have reported four polymorphs (labeled I through IV) and two solvates (hemi-and sesquihydrate) of the API in US patent 6,441,002 (Clas et al, US patent 6,441,002, 2002). However, no crystal structures have been reported for any of these forms. A comparison was made between the PXRD patterns reported in patent `002 and the powder spectra simulated from single crystal data. The two polymorphs characterized here correspond to form I and form IV of the patent. Form II of the patent could not be obtained by us with a variety of experimental conditions. Form III of the patent corresponds to hemihydrate II of this study. Form III is therefore not a polymorph of form I and form IV. What we have termed hemihydrate I in this study is obtained under a wide variety of conditions and it is also the only hemihydrate reported as such in the patent. Because the Etoricoxib molecule contains no conventional hydrogen bond donors, there cannot be any strong hydrogen bonds in the crystal structures of forms I and IV. The packing is accordingly characterized by weak hydrogen bonds of the C-H center dot center dot center dot O=S and C-H center dot center dot center dot N type. Thermal data were collected for form I, form IV and hemihydrate I to shed some light on relative stabilities. PXRD diffractograms show the transformation of form IV to form I at elevated temperature, indicating that form I is more stable than form IV. However, this transformation occurs only in samples of form IV that contain some form I; it does not occur in pure form IV. The formation of the two hemihydrates could follow from the known tendency of an acceptor-rich molecule to crystallize as a hydrate.

Item Type: Journal Article
Publication: CRYSTENGCOMM
Publisher: Royal society of chemistry
Additional Information: Copyright for this article belongs to ROYAL SOC CHEMISTRY, ENGLAND
Department/Centre: Division of Chemical Sciences > Solid State & Structural Chemistry Unit
Date Deposited: 10 Dec 2012 07:11
Last Modified: 10 Dec 2012 07:11
URI: http://eprints.iisc.ac.in/id/eprint/45522

Actions (login required)

View Item View Item